news careers DEVELOPING TRANSFORMATIVE TARGETED CANCER THERAPEUTICS Aravive is currently conducting clinical trials of its lead compound, batiraxcept (formerly AVB-500), in combination with standard anticancer treatments in multiple indications. Now enrolling patients in the AXLerate Phase 3 trial of batiraxcept in platinum-resistant ovarian cancer. Click HERE for the AXLerate Phase 3 Trial LEARN MORE Now enrolling patients in a Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma. LEARN MORE Now enrolling patients in a Phase 1b/2 trial of batiraxcept in pancreatic adenocarcinoma. LEARN MORE Pipeline Batiraxcept, our lead product candidate targets GAS6/AXL signaling, an important driver of metastasis and resistance to anti-cancer drugs. LEARN MORE Patients Our lead indication for batiraxcept is a registrational Phase 3 trial for the treatment of platinum resistant ovarian cancer. We are also evaluating batiraxcept in Phase 1b/2 trials for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. LEARN MORE Investors For the latest news, corporate presentation and investor information, visit the investor section of our site. LEARN MORE ©2021 Aravive Terms of Use | Privacy Policy